Skip to search formSkip to main contentSkip to account menu

aprinocarsen

National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Phosphorothioate Oligonucleotides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2011
2011
The long march of antisense
Antisense therapy has generated waves of enthusiasm and disappointment. With a new drug about to be submitted for approval, is it… 
2008
2008
Dose-dense chemotherapy with trastuzumab is an appropriate option.
2839, 2005 11. Paz-Ares L, Douillard JY, Koralewski P, et al: Phase III study of gemcitabine and cisplatin with or without… 
Review
2007
Review
2007
Enzastaurin , a Protein Kinase C B ^ Selective Inhibitor , and Its PotentialApplicationasanAnticancer AgentinLungCancer
Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling throughprotein kinase C (PKC)-h and the… 
2006
2006
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
The antisense oligonucleotide aprinocarsen specifically inhibits the transcription of protein kinase C-alpha. This study… 
2006
2006
Phase II study of PKC-α antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer
2005
2005
Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced/metastatic non-small cell lung cancer
SummaryAprinocarsen is a specific antisense oligonucleotide inhibitor of protein kinase C-α. This study aimed to evaluate the… 
2005
2005
Randomized phase III trial of gemcitabine/cisplatin (GC) and protein kinase C α (PKCα) antisense oligonucleotide aprinocarsen in patients (pts) with advanced stage non-small cell lung cancer (NSCLC)
7053 Background: Aprinocarsen (Ap; Affinitak) is an antisense oligonucleotide tailored to target PKCα mRNA, thereby inhibiting… 
Review
2004
Review
2004
The role of protein kinase C-alpha (PKC-alpha) in malignancies of the gastrointestinal tract.
Review
2004
Review
2004
The role of protein kinase C-alpha in malignancies of the nervous system and implications for the clinical development of the specific PKC-alpha inhibitor aprinocarsen (Review).
Antisense oligonucleotide (ASO) technology offers a novel approach for the development of anti-cancer drugs. For example, the ASO… 
Review
2003
Review
2003
Targeting Protein Kinase C‐alpha (PKC‐α) in Cancer with the Phosphorothioate Antisense Oligonucleotide Aprinocarsen
Abstract: Antisense oligonucleotides (ASOs) offer a novel pharmacological platform to develop highly specific drugs. As shown by… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)